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Abstract
We have isolated a selectively deglycosylated form of
vitamin D binding protein (DBP-maf ) generated from
systemically available DBP by a human pancreatic
cancer cell line. DBP-maf is antiproliferative for endo-
thelial cells and antiangiogenic in the chorioallantoic
membrane assay. DBP-maf administered daily was able
to potently inhibit the growth of human pancreatic
cancer in immune compromised mice (T/C=0.09). At
higher doses, DBP-maf caused tumor regression.
Histological examination revealed that treated tumors
had a higher number of infiltrating macrophages as well
as reduced microvessel density, and increased levels of
apoptosis relative to untreated tumors. Taken together,
these data suggest that DBP-maf is an antiangiogenic
molecule that can act directly on endothelium as well as
stimulate macrophages to attack both the endothelial
and tumor cell compartment of a growing malignancy.
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Introduction
There is considerable evidence that tumor growth is an
angiogenesis-dependent event [1 ]. Certain tumor-gener-
ated molecules can inhibit tumor growth and induce
dormancy of metastases by inhibiting tumor angiogenesis,
( the growth of new blood vessels into the tumor mass).
These molecules function by inhibiting the migration and
proliferation of endothelial cells. Recently discovered ex-
amples of such angiogenesis inhibitors include angiostatin
[2 ], endostatin [3], and antiangiogenic ATIII [4 ]. Antiangio-
genic therapies hold great potential to prevent the growth of
primary and metastatic disease, as these therapies target
the genomically stable endothelial compartment of a tumor.
Many conventional anticancer therapies lose efficacy over
time, because the genomically unstable population of tumor
cells that they target can acquire drug resistance.
At least three antiangiogenic molecules have been
previously isolated from the conditioned media of tumors
where, clinically, metastases grow rapidly after removal of the
primary disease. Accordingly, we screened several human
pancreatic tumors for the ability to inhibit the growth of a
secondary implant of tumor cells, using a well -established
in vivo model [5 ]. One such tumor, BxPC-3, was able to
inhibit the growth of secondary tumor implants by as much as
80%. Using conventional chromatography techniques, we
isolated an antiangiogenic molecule from the conditioned
media of BxPC-3 cells. Sequence analysis determined that
this protein was the bovine form of vitamin D binding protein
(DBP).
DBP is a multidomain protein that binds vitamin D
metabolite at its amino- terminal domain and actin at its
carboxy- terminal domain [6]. Furthermore, the carboxy-
terminal domain contains an O - linked glycosylation site on a
threonine residue in human DBP [7]. This site is occupied
with a mucin- type trisaccharide, consisting of N -acetylga-
lactosamine with a dibranched galactose and sialic acid.
Sequential hydrolysis of the terminal sialic acid and galactose
results in a molecule with core N -acetylgalactosamine
attached to the threonine residue [7]. Such selective
deglycosylation is shown to occur naturally as part of the
inflammatory response. Membrane-bound b -galactosidase
and sialidase of activated B- and T- lymphocytes can
hydrolyse the terminal galactose and sialic acid [7 ]. The
resultant molecule is a potent activator of macrophages, and
is termed DBP-maf (macrophages activating factor ).
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Previous data have shown that DBP-maf, generated
specifically by selective in vitro deglycosylation, has a role to
play in the treatment of an Ehrlich ascites tumor in a mouse
model [8,9]. Further administration of DBP-maf as an
adjuvant immunotherapy to photodynamic therapy of cancer
[10] had a synergistic effect on tumor cures using a
squamous cell carcinoma model in mice. In both tumor
models, it was hypothesized that DBP-maf elicited its effect
by activating macrophages, which then directly attacked the
tumor cells. We present evidence that BxPC3 pancreatic
cancer cells can generate DBP-maf from DBP indicating
that DBP-maf may be generated in vivo. We further present
evidence suggesting that DBP-maf is anti - tumorigenic
in part through an antiangiogenic mechanism. Further,
DBP-maf, as well as being directly antiangiogenic activates
macrophages which can then infiltrate solid tumors. This
proposed amplification of the antiangiogenic effect of DBP-
maf may explain the currently observed potency of this
molecule as an anti-tumorigenic therapy.
Materials and Methods
Cell Culture and Conditioned Media Collection
Human pancreatic cancer cell lines BxPC-3, SU88.86,
and ASPC-1 (American Type Culture Collection, Rockville,
MD) were incubated in RPMI 1640 (Gibco, Carlsbad, CA)
supplemented with 10% fetal calf serum (FCS) (Gibco), 100
g/ml penicillin G, and 100 g/ml streptomycin (Pharmacia,
Sweden). Cells were maintained in T-75 tissue culture
flasks (Falcon, Bedford, MA) and grown in 5% CO2/95% at
378C in an humidified incubator. Conditioned media were
produced by adding RPMI 1640/5% FCS (100 ml) to near
confluent BxPC-3 cells in 900 cm2 roller bottles (Corning,
Acton, MA), and incubating for 72 hours. Conditioned media
were collected, filtered (0.45 m), and stored at 48C.
Bovine Capillary Endothelial (BCE) Assays
The anti–endothelial activity of protein fractions obtained
during purification procedures was determined using a
proliferation assay. BCE cells were isolated from the cortices
of freshly harvested bovine calf adrenal glands, cultured, and
used from passage 9-14. BCE cells were maintained in
DMEM with 10% heat- inactivated bovine calf serum (BCS),
antibiotics, and 3 ng/ml recombinant human basic fibroblast
growth factor (bFGF) (Scios Nova, CA). Cells were washed
with PBS and dispersed in a 0.05% solution of trypsin. A cell
suspension was made with DMEM/10% BCS/1% antibiotics
and the concentration adjusted to 32,000 cells /ml. Cells
were plated onto gelatinized 24-well culture plates (0.5 ml /
well ) and were incubated at 378C in 10% CO2 for 24 hours.
The media were replaced with 0.5 ml of DMEM/5% BCS/1%
antibiotics, and the test sample applied. After 20 min of
incubation, bFGF was added to each well (1 ng/ /ml ). After
72 hours, cells were dispersed in trypsin, resuspended in
Isoton II (Fisher Scientific, PA) and counted by Coulter
counter.
Chick Chorioallantoic Membrane (CAM) Assay
Chick embryos were prepared as reported [11]. The
sample was dissolved in 0.45% methylcellulose (10 l ) and
micropipetted onto the outer third of the chorioallantoic
membrane of day 6 embryos. This procedure was accom-
plished by using a 3–6 stereoscope. Antiangiogenic
activity was measured by observing the avascular zone
around the sample between 48 and 96 hours.
Purification of Human and Bovine DBP
Human and bovine DBP were purified from respective
sera using 25-hydroxyvitamin D3 affinity chromatography as
described [12] with suitable modifications. Human or bovine
sera was diluted with equal volume of column buffer (50 mM
Tris HCl, pH 8.3, 150 mM NaCl, 1.5 mM EDTA) and applied
to the 25-hydroxyvitamin D3 affinity column at 48C. The
column was washed with the column buffer (20 times the bed
volume) and bound proteins eluted with 1 M acetate buffer,
pH 5.0. The salts were dialyzed away and proteins were
further fractionated on a hydroxyapatite column equilibrated
with 10 mM potassium phosphate buffer, pH 7.0. The column
was washed with excess equlibration buffer and bound DBP
eluted with 75 mM potassium phosphate buffer, pH 7.0.
Purification of DBP-maf from BxPC-3 Conditioned Media
BxPC-3 conditioned media were applied to a 25-hy-
droxyvitamin D3 affinity column (equilibrated with 50 mM Tris
HCl, pH 8.3 buffer at 48C). The column was washed with
RPMI 1640 followed by 50 mM Tris HCl, pH 8.3 buffer.
Bound DBP/DBP-maf was eluted with 1 M acetate buffer,
pH 5.0. The proteins were further purified using hydroxya-
patite chromatography as described above.
Generation of DBP-maf from DBP
Sialidase and b -galactosidase (2 U each) were coupled
to 0.6 g of CNBr activated Sepharose (Pharmacia) accord-
ing to manufacturer’s instructions. The immobilized enzymes
were stored at 48C after a final wash with coupling buffer until
needed.
DBP (100 g) was incubated with a mixture of immobi-
lized sialidase and b -galactosidase (0.2 U of activity each) in
PBS-Mg (10 mM sodium phosphate buffer, pH 5.5, 0.9%
sodium chloride and 1 mM MgSO4) at 378C on an end- to-
end shaker for 2 hours. The gel was sedimented by
centrifugation at 600g at 48C for 5 minutes. The super-
natant was collected and sterilized by filtering through a
0.22-m filter. Possible endotoxin contamination of the
DBP-maf preparations was eliminated by removing endo-
toxin using Detoxi Gel (Pierce, Rockford, IL).
Macrophage Activation Assay
RAW 264.7 cells were plated at a density of 50,000 cells
per well in 24-well plates and grown overnight in RPMI 1640
containing 5% FBS at 378C. The cells were treated with
various preparations of DBP or DBP-maf (1 ng/ml per well )
in buffer containing 1 mg/ml of ovalbumin for 3 hours
(n=6) at 378C. Reduced fluoresceine (dihydrofluoresceine
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diacetate) was added to each well to a final concentration of
2 mM and incubated for a further 1 hour at 378C. The
fluorescence of the cell free supernatant was determined
using a Hitachi F2000 Fluorescence Spectrophotometer
(excitation at 485 nm and emission at 530 nm).
Detection of Glycosidases in BxPC-3 Conditioned Media
Cells (50,000) were washed three times with PBS and
suspended in 1 ml of PBS containing 0.4 mM 2-(4-
methylumbelliferyl ) -a -D-N -acetylneuraminic acid (siali-
dase assay), 2- (4-methylumbelliferyl ) -b -D-galactoside
(galactosidase assay) for 4 hours at 258C with mixing. At
the end of 4 hours, 0.2 ml of the reaction mixture was
withdrawn into a clean tube and the reaction stopped by
adding 1 ml of ethanol. The tubes were centrifuged and the
supernatant collected. 1 M NaOH (25 l ) was added to the
supernatant. The fluorescence emission was measured at
450 nm. The excitation was at 365 nm. Values were
expressed as arbitrary fluorescence units.
Animal Studies
All animal work was performed in the animal facility at
Children’s Hospital, Boston in accordance with federal, local,
and institutional guidelines. Male 6 to 8 weeks old immune-
compromised mice (SCID, Mass General Hospital, Boston,
MA) were acclimated, caged in groups of four or less in a
barrier care facility and their backs were shaved. All mice
were fed a diet of animal chow and water ad libitum. Animals
were anesthetized with methoxyflurane (Pittman-Moore,
Mundelein, IL) before all procedures and observed until fully
recovered. Animals were euthanized by CO2 asphyxiation.
Double Side Tumor Model
A primary tumor of pancreatic cancer cells was generated
by injecting 2.5106 cells (0.2 ml) in the left flank. Tumors
were measured with a dial -caliper, and volumes were
determined using the formula width2length0.52. When
the tumor volume was at least 400 to 500 mm3 (2% to 2.5%
of body weight ), which occurred within 14 to 21 days, the
secondary tumor was transplanted into the contralateral
flank (2.5106 cells in 0.2 ml). Control mice received an
identical injection of secondary tumor cells at the same time.
Tumors were measured every third day. The extent of
suppression of the secondary tumor by the primary tumor
was calculated as the difference in tumor volume.
Tumor Cell Implantation and Treatment
A tumor cell suspension of 2.5106 cells in 0.2 ml RPMI
1640 was injected into the subcutaneous dorsa of mice in the
proximal midline. The mice were weighed and tumors were
measured as described above, blinded, every 3 to 5 days in
two diameters with a dial -caliper. When the tumor volumes
were approximately 100 mm3, mice were randomized into
different groups. Experimental groups received DBP-maf at
the stated dose in 0.2 ml PBS, administered intraperito-
neally. The control group received comparable injections of
saline or human DBP, expressed in Escherichia coli. Tumors
were measured every third to fifth day and the ratio of treated
to control tumor volume (T/C) was determined for the last
time point.
Histology
Mice were killed at the end of the experiments. Repre-
sentative tumor tissues ( three of each group) were harvested
and fixed in 10%neutral buffered formalin at 48C for 12 hours.
All tissues were paraffin embedded. Sections (5 m) were
first stained with hematoxylin -eosin to evaluate tissue
viability and quality. Themicrovessel density was determined
by immunocytochemical staining using a Vectastain avidin-
biotin detection system (Vector Labs, Burlingame, CA) with
anti -CD 31 (monoclonal, dilution: 1:250, Pharmingen, San
Diego, CA) according to the manufacturers’ instructions. At
low magnification (40 to 100), regions of highest vessel
density ( ‘‘hot spot’’ regions) were scanned and counted at
200magnification (0.738mm2 field) by an observer who did
not know the treatment schedule. At least six fields were
counted in a representative tumor section and the highest
count was taken. Tumor sections were stained for prolifer-
ation with anti -PCNA (monoclonal, dilution: 1:50, Signet,
Dedham, MA) or for apoptosis with terminal deoxynucleotide
transferase (TUNEL) (Apotag; Intergen, Purchase, NY).
They were evaluated at low magnification for viable regions.
PCNA-positive (red stain) and apoptotic tumor cells (brown
stain) were counted at400magnification and expressed as
a percentage of the total cells in the field. At least 1000 cells in
six random fields were counted. Macrophages were immu-
nostained with either rat anti–mouse Mac-3 antiserum
(1:200, Pharmingen) or with rat anti–mouse cd45 antiserum
( leukocyte common antigen, Ly-501:100, Pharmingen). After
the same secondary antibody as above, avidin-biotin
conjugated to alkaline phosphatase (Vector ) was used with
a New Fuschin chromagen (BioGenex, San Ramon, CA).
Statistics
The rate of tumor growth was plotted against treatment
day. Analysis of covariance on the rate of change was used
to compare the slopes for the treated and the control groups.
Student’s t test analysis was used to compare the mean
microvessel density, TUNEL staining, and PCNA staining
between control and treated groups.
Table 1. Inhibition of Secondary Tumor Growth by a Primary Pancreatic
Cancer Tumor in an In Vivo Mouse Model.
Primary Tumor Secondary tumor
Lewis lung HT1080 BxPC3
BxPC3 84% 73% 81%
ASPC-1 10% 7% Not determined
Tumor cells were prepared and implanted into SCID mice. At the end of the
experiment, tumor volume was measured. The volume of an inhibited tumor
was compared to the volume of an uninhibited control tumor, and the ratio
expressed as percentage inhibition. Thus, a secondary tumor having a
volume that is 16% of the control tumor volume exhibits 84% inhibition in
growth.
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Results
Purification of Anti–Endothelial DBP-maf from Pancreatic
Cancer Cell Conditioned Media
The pancreatic cancer cell line, BxPC-3, was able to
inhibit the growth of a secondary tumor implant by up to 80%
(Table 1) as determined in an in vivomodel in extensive use
in our laboratory. A different pancreatic cancer cell line
(ASPC-1) was unable to inhibit the growth of secondary
tumors, suggesting that BxPC-3 was producing a circulating
tumor-suppressive activity. However, the conditioned media
obtained from BxPC-3 cells were unable to inhibit the
proliferation of endothelial cells (data not shown). This was
possibly due to the relatively high concentrations of growth
factors such as bFGF (6 to 8 pg/ml) and VEGF (3000 to
6000 pg/ml) present in the conditioned media after 24 to 48
hours. These proangiogenic cytokines bind heparin. We
therefore fractionated the conditioned media on heparin-
Sepharose. Material that did not bind to heparin-Sepharose
exhibited anti–endothelial activity as determined using an
endothelial cell proliferation assay. This activity was further
purified using a combination of Q-Sepharose and monoQ
anion exchange chromatography. Importantly, media con-
taining 5% FCS did not contain any anti–endothelial activity
when fractionated using the same protocol (Figure 1a ).
Anti–endothelial fractions eluting from the monoQ column
(Figure 1b ) exhibited two bands by SDS-PAGE (Figure 1c ).
These two proteins were resolved using C4 RP-HPLC. Mass
spectrometry and sequence analysis indicated that one of
the proteins (Mr 66,042) was BSA, whereas the other protein
(Mr 53,454) had the amino- terminal sequence LERGR-
DYEKD. This sequence is 90% similar to the amino-terminal
sequence of human DBP. We assigned an identity of bovine
DBP to our anti–endothelial protein.
Selective Deglycosylation Converts DBP to an
Antiangiogenic Factor
Bovine DBP purified from BxPC-3 conditioned media was
able to inhibit the proliferation of endothelial cells with an
apparent IC50 value of 5 to 10 g/ml (Figure 2a ). However,
bovine DBP purified from BCS was unable to inhibit the
proliferation of endothelial cells (Figure 2a ).
Similarly, human DBP, expressed in an E. coli system,
was unable to inhibit angiogenesis in the CAM (data not
shown). Thus, we hypothesized that the BxPC-3 cells were
modifying bovine DBP in some way to generate an anti–
endothelial protein. A known biochemical modification of
DBP is deglycosylation to produce DBP-maf. Furthermore,
it is well known that certain cancer cells can produce gly-
cosidases. BxPC-3 cells produce sialidase (40750±353
fluorescent units, see Materials and Methods section) and b -
galactosidase (8570±86 fluorescent units, see Materials
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Figure 1. Purification of anti –endothelial factor from human pancreatic
cancer cell, BxPC -3. BxPC -3 conditioned media ( 1 L conditioned for 48
hours at 37 8C in the presence of 5% FCS) were applied to a HiTrap ( 5 ml )
heparin -Sepharose column (Pharmacia ) equilibrated in 50 mM Tris, pH 7.4.
The unbound material contained anti –endothelial activity, as assayed by an
endothelial cell proliferation assay. This activity ( ) was further purified using
Q-Sepharose (a ) and monoQ anion exchange chromatography ( b ). Note
that control media containing 5% FCS exhibited no anti –endothelial activity
(6 ) when subjected to the fractionation protocol. The fraction exhibiting anti –
endothelial activity ( ) eluting from monoQ at 0.2 M NaCl ( from a
continuous gradient of NaCl ) contained two bands ( c ). These bands were
very similar in migration and pI. They were resolved from each other using C4
RP -HPLC, and sequence analysis, coupled with mass spectrometry analysis,
determined that they were BSA and a protein with 90% homology to human
vitamin D binding protein within the amino terminal 10 residues. We therefore
assigned an identity of bovine vitamin D binding protein to this band.
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and Methods section). To test this hypothesis, we purified
human DBP, deglycosylated it using immobilized b -galacto-
sidase and sialidase as described (see Materials and
Methods section), and tested this DBP-maf in the CAM
assay. DBP-mafwas able to inhibit angiogenesis in the CAM
assay (Figure 2b ).
DBP Purified from BxPC-3 Conditioned Media can Activate
Macrophages in a Similar Manner to Human and Bovine
DBP-maf
To confirm that BxPC-3 cells were able to convert DBP to
the deglycosylated macrophage activating factor form, we
tested the ability of DBP purified from BxPC-3 conditioned
media to activate macrophages. Human and bovine DBP
were purified as described, and enzymatically converted to
DBP-maf. These DBP-maf proteins were able to activate
macrophages (Figure 3) as determined by a superoxide
generation assay (see Materials and Methods section). The
increase in superoxide generation by macrophages exposed
to DBP-maf was three- to four - fold. DBP purified from
BxPC-3 conditioned media activated macrophages, with a
similar increase in superoxide production of three- to four-
fold over bovine DBP (Figure 3). These data indicate that the
DBP purified from BxPC-3 conditioned media has been
converted to the DBP-maf form.
Systemically Administered DBP-maf is Able to Inhibit the
Growth of Solid Tumors
Tumors were implanted on the flank of amouse, and when
the tumor had attained a volume of 100 mm3, therapy was
started. Control animals received saline or E. coli expressed
human DBP and treated animals received intraperitoneal
injection of DBP-maf (4 ng/kg per day) for 28 to 30 days. The
growth of human pancreatic tumors (BxPC-3 and SU88.86)
in immune compromised mice was inhibited significantly
(Figure 4, a and b ), with essentially no growth of the treated
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Figure 2. Inhibition of angiogenesis in a BCE proliferation assay and the CAM assay by DBP-maf but not DBP. Bovine DBP (6 ) purified from BxPC-3 conditioned
media was able to inhibit proliferation of BCE cells in a dose -dependent manner, whereas DBP ( ) purified from bovine serum, diluted in control media, was unable
to inhibit proliferation as effectively. Note that there is a slight inhibition at higher concentrations of DBP (a ). Purified human DBP and selectively deglycosylated
human DBP-maf were tested in the CAM assay at 1 and 10 g. Note that there are substantial zones of angiogenesis inhibition in the CAM treated with DBP-maf
(b ). These images are representative of at least five assays performed at each dose.
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tumor observed over the course of the experiment [P<.001
as determined by analysis of covariance (see Materials and
Methods section) ]. The growth of Lewis Lung carcinoma in a
normal C57BL6/J mouse was also markedly inhibited by
DBP-maf at this dose although there was a measurable
increase in the volume of the treated tumor over the course of
the experiment (data not shown). We observed a dose
response to the therapy when we treated BxPC-3 tumors
(Figure 4c ). Animals receiving human DBP expressed in
E. coli exhibited tumor growth, whereas animals receiving
the maximum dose in this experiment (4 g/kg per day)
showed no growth of established tumors with evidence of
regression of established tumors [P<.001 as determined
by analysis of covariance (see Materials and Methods
section) ]. Animals receiving 4 ng/kg per day also exhibited
little or no tumor growth even after 24 days on therapy,
whereas animals receiving 4 ng/kg every 4 days displayed
some growth in established tumors (Figure 4c ).
Histology Results
Histological analysis showed that treated tumors were
comprised mainly of a small necrotic cyst with a layer of
viable tumor cells at the outer perimeter, adjacent to a layer
of healthy connective tissue (Figure 5b, arrowed ). Untreated
tumors (Figure 5a ) showed no such morphology, instead
comprising a mass of viable tumor cells. Furthermore,
immunostaining directed against the macrophage specific
marker Mac-3 revealed that treated tumors had been
infiltrated by macrophages (Figure 5d, arrowed ), whereas
control tumors had much reduced staining for this antigen
(Figure 5c ). Staining for another macrophage marker,
leukocyte common antigen, which will also stain NK-cells,
also showed infiltration of the treated tumor by cells of
leukocyte origin (Figure 5, f and e ).
Histological sections of treated and control tumors were
analyzed for endothelial cells (CD 31), proliferation (PCNA),
and apoptosis (TUNEL). Our data demonstrated a signifi-
cant difference in the microvessel density between the
treatment and the control groups as assessed by t test
analysis. In control BcPC-3 tumors treated with PBS, the
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Figure 3. Macrophage activation by DBP -maf variants. Various DBP
preparations were generated and tested for their ability to activate macro-
phages, as measured by a superoxide production assay human DBP [1 ] and
bovine DBP [3 ] were unable to activate macrophages. Human DBP-maf [ 2 ]
and bovine DBP -maf [ 4 ] were able to activate macrophages. Bovine DBP
purified from BxPC-3 conditioned media [ 5 ] was also able to activate
macrophages. Each value is the mean of quadruplicates, and these data are
representative of at least three separate experiments.
Figure 4. Treatment of tumors with DBP -maf. BxPC -3 cells ( a ) and SU88.86
cells ( b ) were implanted subcutaneously onto the flank of a SCID mouse.
Once the tumors had attained a volume of 100 mm3, treatment was started.
Animals were given 4 ng / kg per day of DBP -maf (6 ). Therapy was
administered intraperitoneally. Control animals ( ) received saline injections
only. n=3. BxPC -3 cells were implanted subcutaneously onto the flank of a
SCID mouse ( c ). Once the tumor had attained a volume of 100 mm3,
treatment was started. Animals received intraperitoneal injections of DBP-
maf at 4 ng / kg every 4 days (6 ), 4 ng / kg per day (& ), or 4 g / kg per day
(5 ). Control animals received 4 g / kg per day of E. coli expressed human
DBP ( ). n=5.
Neoplasia . Vol. 5, No. 1, 2003
Vitamin D Binding Protein-Macrophage Activating Factor (DBP-maf ) Kisker et al. 37
microvessel density per high power field was 133.39±9.3,
whereas the DBP-maf (4 g/ml) treated group had a value
of 34±5.56 (P<.001). There was no significant difference in
the proliferation rate between control tumors (59.27±2.96)
and tumors treated with DBP-maf (60.72±2.46) (P<.5). In
contrast, the apoptotic index of treated tumors was signifi-
cantly higher (3.21±0.38) than in the control group
(0.86±0.13: P<.001). These data show that in the tumors
in which angiogenesis is inhibited, the high level of tumor cell
proliferation in all groups is balanced by an increased
apoptotic index and a simultaneously decreasedmicrovessel
density in the therapy group.
Discussion
DBP purified from the conditioned media of human pancre-
atic cancer cells BxPC-3 is able to activate macrophages.
Our data indicate that glycosidases produced by BxPC-3
pancreatic carcinoma cells generate active DBP-maf from
its fully glycosylated precursor, present in plasma and in
tissue culture serum. DBP-maf is antiangiogenic in the CAM
assay. Interestingly, nonglycosylated recombinant DBP
expressed in E. coli has no antiangiogenic activity suggest-
ing that some residual carbohydrate is necessary for
antiangiogenic activity. DBP-maf, generated from purified
human DBP, was effective as an anti–tumorigenic drug.
Administration of low daily doses (4 ng/kg) of DBP-maf
caused marked inhibition of solid tumor growth in murine
models. Furthermore, DBP-maf was able to regress estab-
lished pancreatic tumors in immune compromised mice
when administered at higher doses. Histological examina-
tions of treated and control tumor specimens revealed that
tumors treated with DBP-maf had a low microvessel density,
and substantial macrophage infiltration into the tumor mass.
Conversely, untreated tumors had little observable macro-
phage infiltration into a highly vascularized tumor mass.
Treated tumors also demonstrated an increase in apoptotic
index as compared to control tumors.
DBP-maf has been used successfully to treat Ehrlich
ascites tumor in a mouse model [8,9]. Although DBP-maf
showed no efficacy against a squamous cell carcinoma in
a murine model when administered alone [10], it proved to
be curative when administered as an adjuvant to photo-
dynamic therapy. We now show that tumor-dependent
DBP-maf inhibits pancreatic cancer at doses as low as
4 ng/kg per day.
This selectively deglycosylated form of the protein also
activates macrophages [13]. We have also shown that
DBP-maf, either generated enzymatically or purified from
BxPC-3 conditioned media, can activate macrophages.
Macrophages are terminally differentiated cells that produce
a number of potent angiogenic cytokines and growth factors
as well as ECM degrading enzymes. Thus, macrophages
can influence various stages of angiogenesis either pos-
itively or negatively [14]. There are also differences in the
angiogenic potential of classically versus alternatively acti-
vated macrophages [15]. Alternatively activated macro-
phage-rich lesions tend to be highly vascularized, whereas
classically activated macrophage-rich lesions tend not to be
[14]. Our histology data do show a poorly vascularized,
macrophage-rich tumor mass in the case of DBP-maf
treated tumors. This obvious targeting of the tumor by
activated macrophages may help explain the potency of this
therapy against tumors. The additional macrophage activat-
ing activity may also explain why the in vivo anti– tumor
activity is observed at substantially lower doses than in vitro
anti–endothelial activity.
The activated macrophages may secrete an antiangio-
genic factor that contributes to the potency of this molecule.
The identity of this factor is unknown at present. We assayed
the DBP-maf stimulated macrophage conditioned media
for cytokines known to have a role in angiogenesis. DBP-
maf did not induce the secretion of IFNg or IL-12, both of
which were undetectable by ELISA in the macrophage
conditioned media (data not shown). The absence of IFNg in
the macrophage conditioned media argues against the direct
involvement of this cytokine and also any involvement of
IL-18. IL-18 is reported to be antiangiogenic and antitumori-
genic [16]. However, it is a potent IFNg - inducing cytokine,
thus, one would expect to find IFNg if IL-18 was involved. IL-
12 has also been shown to be a potent antiangiogenic
cytokine [17] which again mediates its effect by inducing
IFNg. We have directly demonstrated the absence of
Figure 5. Histological examination of control and treated tumors. Control
untreated BxPC-3 tumor (a ) and DBP-maf - treated tumors ( b ) were stained
with H&E. Staining for the antigen Mac -3 revealed few macrophages in
control tumors ( c, arrow ), whereas heavy infiltration of macrophage cells into
the treated tumor (d ) was apparent ( arrow ). Staining for leukocyte common
antigen also showed heavy infiltration of DBP-maf - treated tumors by cells of
leukocyte origin ( f ). Control tumors stained poorly for this antigen (e ). In all
panels, the bar is 40 m except the first panel in b ( 400 m).
38 Vitamin D Binding Protein-Macrophage Activating Factor (DBP-maf ) Kisker et al.
Neoplasia . Vol. 5, No. 1, 2003
IL-12 in the conditioned media of macrophages exposed to
DBP-maf.
It has been hypothesized that DBP-maf activates macro-
phages as the first step in an immune developmental
process involving macrophages acting as antigen presenta-
tion cells and lymphocytes generating antibodies against
tumor antigens [10,18]. It has been suggested that the
effectiveness of multiple administrations of DBP-maf against
Ehrlich ascites tumor was due to a developed immunity
against the tumor [8 ]. In support of this concept, Ehrlich
ascites tumor cells cannot grow in mice previously immu-
nized with killed Ehrlich ascites [19]. It is also known that the
tumoricidal capacity of macrophages is observed preferen-
tially through the IgG (Fc-receptor ) -mediated pathway
[20–22] and DBP-maf is a potent adjuvant in immunization
for antibody production. However, we have observed anti–
tumorigenic activity with DBP-maf therapy in immune
compromised mice, deficient in B and T lymphocytes. Such
an observation argues against a wholly immune-mediated
mechanism. Furthermore, we saw no anti–proliferative
effect against pancreatic cancer cells by DBP-maf itself
(data not shown). Based on the observed anti–endothelial
activity and antiangiogenic activity of DBP-maf presented
here, we argue for another mechanism, which we hypothe-
size to be antiangiogenic.
While we were preparing this manuscript, another
laboratory published data demonstrating that DBP-maf is
indeed antiangiogenic [23]. They demonstrated that DBP-
maf can inhibit not only endothelial cell proliferation, but also
tube formation, and chemotaxis stimulated by bFGF,
angiopoietin-2, and VEGF. Furthermore, DBP-maf was
able to inhibit angiogenesis in the corneal pocket assay. By
using specific monoclonal antibodies, they were able to
implicate CD36 as a potential receptor of DBP-maf and
mediator of this antiangiogenic effect.
It has been noted that cancers can secrete endo and
exoglycosidases [24–26]. Evidence has been presented
showing that cancerous cells secrete an a -N -acetylgalac-
tosaminidase which cleaves the entire O - linked oligosac-
charide from DBP. Such a deglycosylation renders the
molecule incapable of being converted to DBP-maf. It has
been speculated that this may be a mechanism whereby a
cancer can evade an inflammatory response [18]. In fact, the
presence of a -N -acetylgalactosaminidase activity in the
bloodstream of a cancer patient can serve as a prognostic
index for the disease [18]. It is not surprising then that a
cancer cell may also be able to secrete the enzymes
responsible for efficient conversion of DBP to DBP-maf.
Thus, BxPC-3 in secreting glycosidases capable of gen-
erating DBP-maf from DBP may be enhancing a regulatory
mechanism for the fine control of angiogenesis at inflamma-
tory sites.
In conclusion, a human pancreatic cancer cell line is
capable of generating DBP-maf from DBP. This molecule
has inherent antiangiogenic activity and can stimulate
macrophages. Systemic administration of DBP-maf can
inhibit the rate of tumor growth of various solid tumors and
can, in some cases, cause regression of established tumors.
Such tumor inhibition and regression was observed in
immunocompromised mice, arguing against a wholly im-
mune response-mediated mechanism. We believe that
DBP-maf is working, at least in part through an antiangio-
genic mechanism and that this antiangiogenic mechanism
may be amplified by DBP-maf activated macrophages.
DBP-maf has efficacy as an anti– tumorigenic therapy at
relatively low doses in mice compared to other antiangio-
genic therapies [27,28]. Further characterization and study
of this promising potential drug will hasten its progress
to clinical applications for diseases with an angiogenic
component, including but not limited to the treatment of
cancer.
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